Solid Biosciences Inc. (SLDB) stock
SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.23−0.25 (-3.86%)
Close on Nov 17, 2026Market cap $668.01MP/E –Yield –
Solid Biosciences cash
Cash and short-term investments held at the end of each period.
Solid Biosciences's cash was $377.70M at Jun 30, 2026. For fiscal 2025 it was $187.90M, up 26.2% from the year before. Over ten years it grew 20.7% a year on average. The highest annual figure on record is $213.72M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $187.90M | +26.2% |
| FY2024 | Dec 31, 2024 | $148.90M | +20.4% |
| FY2023 | Dec 31, 2023 | $123.64M | -42.1% |
| FY2022 | Dec 31, 2022 | $213.72M | +2.9% |
| FY2021 | Dec 31, 2021 | $207.78M | +34.0% |
| FY2020 | Dec 31, 2020 | $155.07M | +85.7% |
| FY2019 | Dec 31, 2019 | $83.52M | -31.8% |
| FY2018 | Dec 31, 2018 | $122.46M | +77.1% |
| FY2017 | Dec 31, 2017 | $69.16M | +781.8% |
| FY2016 | Dec 31, 2016 | $7.84M | -72.6% |
| FY2015 | Dec 31, 2015 | $28.60M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $377.70M | +40.9% |
| Q1 FY2026 | Mar 31, 2026 | $380.70M | +24.0% |
| Q4 FY2025 | Dec 31, 2025 | $187.90M | +26.2% |
| Q3 FY2025 | Sep 30, 2025 | $236.10M | +38.0% |
| Q2 FY2025 | Jun 30, 2025 | $268.10M | +40.9% |
| Q1 FY2025 | Mar 31, 2025 | $306.90M | +48.9% |
| Q4 FY2024 | Dec 31, 2024 | $148.90M | +20.4% |
| Q3 FY2024 | Sep 30, 2024 | $171.10M | +19.7% |
| Q2 FY2024 | Jun 30, 2024 | $190.30M | +18.8% |
| Q1 FY2024 | Mar 31, 2024 | $206.10M | +11.1% |
| Q4 FY2023 | Dec 31, 2023 | $123.64M | -42.1% |
| Q3 FY2023 | Sep 30, 2023 | $142.88M | +0.5% |
| Q2 FY2023 | Jun 30, 2023 | $160.19M | -1.7% |
| Q1 FY2023 | Mar 31, 2023 | $185.51M | +3.0% |
| Q4 FY2022 | Dec 31, 2022 | $213.72M | +2.9% |
| Q3 FY2022 | Sep 30, 2022 | $142.16M | -38.1% |
| Q2 FY2022 | Jun 30, 2022 | $162.88M | -34.6% |
| Q1 FY2022 | Mar 31, 2022 | $180.05M | -32.9% |
| Q4 FY2021 | Dec 31, 2021 | $207.78M | +34.0% |
| Q3 FY2021 | Sep 30, 2021 | $229.76M | +826.6% |
| Q2 FY2021 | Jun 30, 2021 | $248.96M | +510.7% |
| Q1 FY2021 | Mar 31, 2021 | $268.50M | +401.0% |
| Q4 FY2020 | Dec 31, 2020 | $155.07M | +85.7% |
| Q3 FY2020 | Sep 30, 2020 | $24.80M | -76.5% |
| Q2 FY2020 | Jun 30, 2020 | $40.77M | -39.5% |
| Q1 FY2020 | Mar 31, 2020 | $53.59M | -43.4% |
| Q4 FY2019 | Dec 31, 2019 | $83.52M | -31.8% |
| Q3 FY2019 | Sep 30, 2019 | $105.66M | -27.3% |
| Q2 FY2019 | Jun 30, 2019 | $67.39M | -58.6% |
| Q1 FY2019 | Mar 31, 2019 | $94.74M | -48.1% |
| Q4 FY2018 | Dec 31, 2018 | $122.46M | +77.1% |
| Q3 FY2018 | Sep 30, 2018 | $145.37M | +868.0% |
| Q2 FY2018 | Jun 30, 2018 | $162.76M | +397.5% |
| Q1 FY2018 | Mar 31, 2018 | $182.38M | +523.2% |
| Q4 FY2017 | Dec 31, 2017 | $69.16M | +781.8% |
| Q3 FY2017 | Sep 30, 2017 | $15.02M | -47.5% |
| Q2 FY2017 | Jun 30, 2017 | $32.72M | – |
| Q1 FY2017 | Mar 31, 2017 | $29.27M | – |
| Q4 FY2016 | Dec 31, 2016 | $7.84M | – |
| Q4 FY2015 | Dec 31, 2015 | $28.60M | – |
See a number that looks wrong?